Sugi Predict

Sugi Predict / Compounds / SCHEMBL2698043

SCHEMBL2698043

SCHEMBL2698043

N#Cc1cc(O)cnc1Cl

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.53
▸ NPSR1 Q6W5P4 2/20 0.53
▸ TDP1 Q9NUW8 2/20 0.53
▸ KHK P50053 1/20 0.39
▸ CSNK1A1 P48729 1/20 0.37
▸ CLK4 Q9HAZ1 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ CHEK1 O14757 1/20 0.37
▸ CYP11B2 P19099 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ ESR1 P03372 3/20 0.33
▸ ESR2 Q92731 3/20 0.33
▸ SYK P43405 1/20 0.33
▸ XDH P47989 1/20 0.33
▸ AURKA O14965 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30506756 1.00 ALDH1A1 (0.53) ALDH1A1NPSR1TDP1KHKCSNK1A1
SCHEMBL1031743 0.78 ALDH1A1 (0.56) ALDH1A1NPSR1TDP1KHKCSNK1A1
SCHEMBL30681117 0.78 ALDH1A1 (0.56) ALDH1A1NPSR1TDP1KHKCSNK1A1
SCHEMBL7216099 0.77 ALDH1A1 (0.55) ALDH1A1NPSR1TDP1KHKCSNK1A1
SCHEMBL30681150 0.77 ALDH1A1 (0.55) ALDH1A1NPSR1TDP1KHKCSNK1A1
SCHEMBL23888650 0.75 CSNK1A1 (0.41) ALDH1A1KHKCSNK1A1CLK4CHEK1
SCHEMBL165874 0.75 ALDH1A1 (0.53) ALDH1A1NPSR1TDP1KHKCSNK1A1
SCHEMBL4064950 0.75 ALDH1A1 (0.53) ALDH1A1NPSR1TDP1KHKCSNK1A1
SCHEMBL30912110 0.75 ALDH1A1 (0.53) ALDH1A1NPSR1TDP1KHKCSNK1A1
SCHEMBL7256746 0.75 ALDH1A1 (0.53) ALDH1A1NPSR1TDP1KHKCSNK1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078119-A1 DEGRADER COMPOUNDS AND USES THEREOF BRISTOL MYERS SQUIBB CO (US) 2026-03-19 — — US disclosed
EP-4688771-A1 NOVEL FAK DEGRADER COMPOUNDS AND USES THEREOF Bristol-Myers Squibb Company (US) 2026-02-11 — — EP disclosed
US-20250282781-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2025-09-11 — — US disclosed
US-12344610-B2 APOL1 inhibitors and methods of use MAZE THERAPEUTICS, INC. (US) 2025-07-01 — — US disclosed
WO-2024249254-A2 METHODS OF USING APOL1 INHIBITORS MAZE THERAPEUTICS, INC. (US) 2024-12-05 — — WO disclosed
US-20240400565-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2024-12-05 — — US disclosed
EP-4465982-A2 APOL1 INHIBITORS AND METHODS OF USE Maze Therapeutics, Inc. (US) 2024-11-27 — — EP disclosed
US-11976067-B2 APOL1 inhibitors and methods of use MAZE THERAPEUTICS, INC. (US) 2024-05-07 — — US disclosed
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 — — US disclosed
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 — — US disclosed
US-20120107275-A1 FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2012-05-03 — — US disclosed
US-20120107275-A1 FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2012-05-03 — — US disclosed
EP-2231663-A2 FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE AS C-MET INHIBITORS Amgen, Inc (US) 2010-09-29 — — EP disclosed
US-20090318436-A1 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2009-12-24 — — US disclosed
US-20090318436-A1 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2009-12-24 — — US disclosed
US-20090318436-A1 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2009-12-24 — — US disclosed
WO-2009091374-A2 FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2009-07-23 — — WO disclosed
WO-2009091374-A2 FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2009-07-23 — — WO disclosed
US-4374140-A 2-Substituted propoxy-3-cyano-5-hydroxypyridines and use as antihypertensives MERCK & CO., INC. (US) 1983-02-15 — — US disclosed
US-4329351-A 2-Substituted propoxy-3-cyano-5-RO-pyridines and intermediates MERCK & CO., INC. (US) 1982-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318436-A1 Fused heterocyclic derivatives and methods of use HGF, HGFAC, MET ALDH1A1 156/4885NPSR1 3050/4885TDP1 2774/4885
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, LDLR ALDH1A1 2642/4885NPSR1 1513/4885TDP1 761/4885
US-20260078119-A1 DEGRADER COMPOUNDS AND USES THEREOF CTTN, SRC, PTK2 ALDH1A1 4164/4885NPSR1 565/4885TDP1 2732/4885
US-12344610-B2 APOL1 inhibitors and methods of use APOL1, APOB, PON1 ALDH1A1 2427/4885NPSR1 1607/4885TDP1 798/4885
US-11976067-B2 APOL1 inhibitors and methods of use APOL1, APOB, LDLR ALDH1A1 2642/4885NPSR1 1513/4885TDP1 761/4885
US-20250282781-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, PON1 ALDH1A1 2427/4885NPSR1 1607/4885TDP1 798/4885
US-20240400565-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, PON1 ALDH1A1 2427/4885NPSR1 1607/4885TDP1 798/4885
US-20120107275-A1 FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE HGF, HGFAC, MET ALDH1A1 156/4885NPSR1 3050/4885TDP1 2774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.